★ WIDE MOAT STOCKS COMPARISON ★

Checking

Stock Comparison

GSK plc vs Novartis AG

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

GSK plc

GSK · London Stock Exchange

Market cap (USD)$104.9B
Gross margin (TTM)73.3%
Operating margin (TTM)24.1%
Net margin (TTM)14.5%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryGB
Data as of2026-08-23
Moat score
57/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into GSK plc's moat claims, evidence, and risks.

View GSK analysis

Novartis AG

NOVN · SIX Swiss Exchange

Market cap (USD)$302.3B
Gross margin (TTM)74.3%
Operating margin (TTM)29.9%
Net margin (TTM)23.1%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryCH
Data as of2026-08-23
Moat score
57/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Novartis AG's moat claims, evidence, and risks.

View NOVN analysis

Comparison highlights

  • Moat score: both at 57 / 100.
  • Segment focus: GSK plc has 3 segments (43.7% in Specialty Medicines); Novartis AG has 5 segments (31% in Oncology).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Strong.
  • Moat breadth: GSK plc has 1 moat types across 1 domains; Novartis AG has 2 across 2.

Primary market context

GSK plc

Specialty Medicines

Market

Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)

Geography

Global

Customer

Hospitals, specialist physicians, payers

Role

Innovator & branded manufacturer

Revenue share

43.7%

Novartis AG

Oncology

Market

Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)

Geography

Global

Customer

Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels

Role

Originator developer, manufacturer, and marketer of oncology therapies

Revenue share

31%

Side-by-side metrics

GSK plc
Novartis AG
Ticker / Exchange
GSK - London Stock Exchange
NOVN - SIX Swiss Exchange
Market cap (USD)
$104.9B
$302.3B
Gross margin (TTM)
73.3%
74.3%
Operating margin (TTM)
24.1%
29.9%
Net margin (TTM)
14.5%
23.1%
Sector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
Drug Manufacturers - General
HQ country
GB
CH
Primary segment
Specialty Medicines
Oncology
Market structure
Competitive
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Strong
Moat score
57 / 100
57 / 100
Moat domains
Legal
Legal, Supply
Last update
2026-08-23
2026-08-23

Moat coverage

Shared moat types

IP Choke Point

GSK plc strengths

No unique moat types yet.

Novartis AG strengths

Capex Knowhow Scale

Segment mix

GSK plc segments

Full profile >

Vaccines

Oligopoly

27.6%

Specialty Medicines

Competitive

43.7%

General Medicines

Competitive

28.7%

Novartis AG segments

Full profile >

Cardiovascular, Renal and Metabolic

Oligopoly

12.6%

Immunology

Oligopoly

19.1%

Neuroscience

Oligopoly

12.5%

Oncology

Oligopoly

31%

Established Brands

Competitive

24.9%

Act on this comparison

Turn a two-stock debate into a systemSee the systematic rankings that surface stocks like GSK and NOVN, with backtests and current holdings.

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.